The Board of Directors at Biocon has approved the unaudited financial results for Q2 2026. Key decisions include the early redemption of Non-Convertible Debentures (NCDs) worth ₹500 Crores, acquisition of Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited, and issuance of Commercial Papers up to ₹550 Crores. The meeting concluded with these approvals, signaling strategic financial moves for the company.
Financial Results for Q2 2026
Biocon’s Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The financial results were prepared per Indian Accounting Standards (Ind-AS). The complete report is available for review.
Early Redemption of Non-Convertible Debentures
The board has approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, totaling ₹500 Crores. These NCDs were issued on a private placement basis on May 19, 2023, and are subject to necessary approvals and consents by January 31, 2026.
Acquisition of Compulsorily Convertible Debentures
The Board has approved the acquisition of 1,06,86,044 Unlisted, Secured, Compulsorily Convertible Debentures (‘CCDs’) of Biocon Biologics Limited (‘BBL’) from ESOF III Investment Fund and EAAA India Alternatives Limited. The face value is ₹10 each, aggregating to ₹300 Crores, and is expected to be completed on or before January 30, 2026, subject to necessary approvals and consents.
Issuance of Commercial Papers
The Board has approved the issuance of Commercial Papers up to an amount not exceeding ₹550 Crores. These will be issued in one or more tranches on a private placement basis.
Source: BSE
